(ANVS)
NYQ – Real Time Price. Currency in USD
2.03
-0.12 (-5.58%)
At close: Mar 27, 2026, 4:00 PM EDT
2.05
+0.02 (0.99%)
After-hours: Mar 27, 2026, 7:56 PM EDT
Get all premium features to the best stock analysis tool
NYQ – Real Time Price. Currency in USD
2.03
-0.12 (-5.58%)
At close: Mar 27, 2026, 4:00 PM EDT
2.05
+0.02 (0.99%)
After-hours: Mar 27, 2026, 7:56 PM EDT
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer’s disease, as well as in phase 3 to treat parkinson’s disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
| Name | Position |
|---|---|
| Dr. Cheng Fang Ph.D. | Senior Vice President of Research & Development |
| Dr. Maria L. Maccecchini Ph.D. | Founder, CEO, President & Executive Director |
| Mr. Mark Patrick Guerin C.M.A., CPA, CFM | Chief Financial Officer |
| Ms. Eve M. Damiano M.S., RAC | Senior Vice President of Regulatory Operations |
| Date | Type | Document |
|---|---|---|
| 2026-03-16 | 8-K | tm268976d1_8k.htm |
| 2026-03-13 | 10-K | anvs-20251231x10k.htm |
| 2026-01-28 | 8-K | tm264292d1_8k.htm |
| 2025-11-13 | 8-K | anvs-20251112x8k.htm |
| 2025-11-12 | 10-Q | anvs-20250930x10q.htm |
| 2025-10-28 | 8-K | tm2529544d2_8k.htm |
| 2025-10-14 | 8-K | tm2528502d2_8k.htm |
| 2025-09-29 | 8-K | tm2527170d1_8k.htm |
| 2025-08-15 | 8-K | tm2523187d1_8k.htm |
| 2025-08-12 | 10-Q | anvs-20250630x10q.htm |